Last update March 9, 2021

C18 H15 ClN2 O2 S

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Non-steroidal anti-inflammatory drug (NSAID), that functions as a selective inhibitor of the cyclooxygenase-2 (COX-2) enzyme.
Prescribed for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.
Daily oral administration in one dose.

We did not find published data regarding the excretion of this substance through breast milk at the time this last update was completed.

Pharmacokinetic data (large volume of distribution and high percentage of protein binding (CINFA 2020, MSD 2017) make it very unlikely for significant quantities to pass into breastmilk.

Until more published data regarding the interactions of this drug and breastfeeding are made available, the use of an alternative drug with a safer pharmacokinetic profile for lactation would be preferable, especially during the neonatal period or with premature infants.

Alternatives

  • Celecoxib (Safe substance and/or breastfeeding is the best option.)
  • Ibuprofen (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

C18 H15 ClN2 O2 S is Etoricoxib in Molecular formula.

Is written in other languages:

Group

C18 H15 ClN2 O2 S belongs to this group or family:

Tradenames

Main tradenames from several countries containing C18 H15 ClN2 O2 S in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 83 - 100 %
Molecular weight 359 daltons
Protein Binding 92 %
VD 1.7 l/Kg
pKa 19.69 -
Tmax 1 - 2 hours
T½ 22 - 25 hours

References

  1. CINFA. Etoricoxib. Ficha técnica. 2020 Full text (in our servers)
  2. MSD. Etoricoxib. Drug Summary. 2017 Full text (in our servers)
  3. Agrawal NG, Porras AG, Matthews CZ, Rose MJ, Woolf EJ, Musser BJ, Dynder AL, Mazina KE, Lasseter KC, Hunt TL, Schwartz JI, McCrea JB, Gottesdiener KM. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol. 2003 Abstract
  4. Rodrigues AD, Halpin RA, Geer LA, Cui D, Woolf EJ, Matthews CZ, Gottesdiener KM, Larson PJ, Lasseter KC, Agrawal NG. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab Dispos. 2003 Abstract

Total visits

1,026

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM